NMS·Healthcare·$492M·#197 / 520 in Healthcare
FDMT 4D Molecular Therapeutics, Inc.
53SPECULATIVE
CATEGORY BREAKDOWN
GROWTH100
QUALITY40
STABILITY41
VALUATION66
GOVERNANCE29
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+230194.6%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
7 months
13
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
4.2%
97
< 25% strong
Price / Sales
Market cap relative to trailing revenue
5.8x
66
< 3x strong
Rule of 40
Growth rate plus operating margin
230007
100
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
3.5%
28
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+12.8%
31
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE FDMT WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when FDMT's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.